---
title: "Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis. Clinical evidence covers ONWARD1, ONWARD2, ONWARD3, STRIDE, STRIDE open-label extension, ACTRN12621000011886, and 6 further headings. 855 evidence topics quoted from 277 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Envudeucitinib

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Moderate-to-severe plaque psoriasis

<a id="topic-1.1.1-1"></a>

##### Summary: prevalence and moderate-to-severe fraction

Two U.S. national surveys each estimate adult psoriasis prevalence at 3.0%:

- 2023 National Health Interview Survey: approximately 3.0% of adults aged 18 years and older reported a history of psoriasis (942 of 29,486 participants), or approximately 7.9 million U.S. adults in 2023.
- NHANES 2011-2014: 3.0% (95% CI, 2.6% to 3.4%) of adults aged 20 years or older, or approximately 7.55 million adults based on 2020 census data. Among adults aged 20 to 59 years, the 2011-2014 estimate of 2.9% did not differ statistically from 2.9% in the 2009-2010 cycle and 3.2% in the 2003-2004 cycle (P = .84).
- An analysis of NHANES 2003-2006 and 2009-2014 and the 2023-2024 National Health Interview Survey (53,225 participants) found no temporal trend in prevalence in any sociodemographic subgroup.
- A separate estimate for U.S. adults aged 20 to 59 years gives a diagnosed prevalence of 3.15% (5 million adults) and an undiagnosed active prevalence of 0.4% (approximately 600,000 adults). U.S. claims-based prevalence ranged from 0.51% to 1.23% depending on the identification algorithm.

Estimates of the moderate-to-severe fraction:

- NHANES 2011-2014: 21.5% of participants reported moderate to severe psoriasis (≥3 palms of body surface area involvement), and the majority reported little or no psoriasis at the time of the survey.
- U.S. adults aged 20 to 59 years: 16.63% of those with a physician diagnosis had moderate to severe disease (3% or greater BSA), an estimated 1.4 million people, and 2.1 million considered psoriasis a large problem in daily life.
- Another analysis: 18.2% (95% CI 12.4 to 25.9) reported moderate or severe disease, 27.3% mild disease, and 54.5% no or little disease.
- Claims analyses: 27.3% moderate to severe and 70.9% mild in one; in another, which assigned severity by treatment type, an estimated 1.7 million insured U.S. patients had moderate to severe psoriasis, of whom 1 million (59%) were not treated in the preceding year.

Globally, 42.98 million people had psoriasis in 2021 in GBD 2021, an increase of approximately 86.4% from 1990, and a separate estimate puts the worldwide number at approximately 125 million. Regional prevalence ranged from 0.14% in east Asia to 1.99% in Australasia, with 1.50% in high income North America.

Source: [Smith et al. (2025)](https://www.jaad.org/article/S0190-9622%2824%2903365-6/fulltext); [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/); [Schneiderman and Derrick (2026)](https://pubmed.ncbi.nlm.nih.gov/42083649/); [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/); [Helmick et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4653077/); [Takeshita et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4549797/); [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/); [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/); [Armstrong and Read (2020b)](https://pubmed.ncbi.nlm.nih.gov/32427307/); [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)

<a id="topic-1.1.1-2"></a>

##### Summary: incidence, natural history, and mortality

- Incidence: in a retrospective cohort identified with electronic health records from 2014 to 2018 (population 2,152,192), incidence was 63.8 (95% CI 61.8 to 65.8) per 100,000 person-years and stable over the 5-year period; it peaked at 92.3 per 100,000 person-years at ages 70 to 79 years and was 75.3 in White, 52.2 in Hispanic/Latino, and 24.9 per 100,000 person-years in Black patients. In a psoriasis cohort whose survival was compared with the Minnesota white population, the age- and sex-adjusted annual incidence was 78.9 per 100,000 and rose from 50.8 per 100,000 in 1970–74 to 100.5 per 100,000 in 1995–1999.
- Incidence across countries and worldwide: adult incidence ranged from 30.3 per 100 000 person years in Taiwan to 321.0 per 100 000 person years in Italy. GBD 2021 counted 5.10 million incident cases worldwide in 2021, a 78.76% increase since 1990, with 8.25 million projected for 2036. An analysis of 1990 to 2019 reported a decrease in the global age-standardized rate (ASR) of psoriasis (AAPC = −0.77), with decreases in all 21 regions.
- Natural history: psoriasis is described as a lifelong disease that “cannot currently be cured”. Onset is bimodal, with peaks around 18-29 and 50-59 years in women and 30-39 and 60-69 or 70-79 years in men; mean age at diagnosis was 43.2 years in the Minnesota-compared cohort.
- Mortality: in one study, severe psoriasis was associated with increased overall mortality (HR, 1.5; 95% CI, 1.3-1.7) and mild psoriasis was not (HR, 1.0), and men and women with severe psoriasis died 3.5 and 4.4 years younger than people without psoriasis. Cause-specific hazard ratios in severe psoriasis were 1.57 for cardiovascular disease, 1.41 for malignancies, 1.65 for infection, and 4.37 for kidney disease, with one extra cardiovascular death per 283 patients per year. Across 12 studies, pooled all-cause mortality RRs were 1.21 in psoriasis, 1.13 in mild psoriasis, and 1.52 in severe psoriasis, and cardiovascular mortality RRs of 1.15, 1.05 (95% CI 0.92-1.20), and 1.38. Another study reported an adjusted HR of 1.99 (95% CI, 1.01-3.93) over a median follow-up of 52.3 months, while survival in the Minnesota-compared cohort was similar to that expected (SMR 0.95, 95% CI 0.84 to 1.07).

Source: [Burshtein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33253841/); [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/); [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/); [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/); [GBD 2019 IMID Collaborators (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10507198/); [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/); [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/); [Gelfand et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18086997/); [Abuabara et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2966545/); [Mehta et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2894736/); [Dhana et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30590074/); [Semenov et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/31415837/)

<a id="topic-1.1.1-3"></a>

##### Summary: comorbidities

- Psoriatic arthritis: across 266 studies of 976,408 people with psoriasis, the pooled proportion with PsA was 19.7% (95% CI, 18.5%-20.9%), and 19.5% in North American patients; PsA incidence ranged from 0.27 to 2.7 per 100 person-years. In a cohort of 464 participants followed for 8 years, 51 developed PsA (annual incidence 2.7 per 100 psoriasis patients), and a severe psoriasis phenotype and nail pitting were among the predictors. In most patients, psoriasis precedes joint disease by up to 10 years. PsA was present in 22.1% of 5,492 people with moderate-to-severe psoriasis in OptumHealth claims.
- Cardiovascular disease: myocardial infarction incidence per 1000 person-years was 3.58 in controls, 4.04 in mild psoriasis, and 5.13 in severe psoriasis, and the adjusted RR of myocardial infarction with severe psoriasis was 3.10 at age 30 and 1.36 at age 60. Severe psoriasis was associated with cardiovascular mortality (RR, 1.39), myocardial infarction (RR, 1.70), and stroke (RR, 1.56), and psoriasis with an estimated excess of 11,500 major adverse cardiovascular events each year.
- Metabolic disease: psoriasis was associated with diabetes (OR 1.59; 1.53 in mild and 1.97 in severe psoriasis; RR 1.27 for incident diabetes), metabolic syndrome (OR 2.26, with a dose-response relationship by severity), and non-alcoholic fatty liver disease (OR 1.96). In the OptumHealth claims cohort, hyperlipidemia (33.3% vs. 27.3%), hypertension (32.8% vs. 23.5%), diabetes (15.8% vs. 9.7%), and obesity (4.8% vs. 2.3%) were more frequent than in matched controls.
- Inflammatory bowel disease: odds ratios were 1.70 for Crohn disease and 1.75 for ulcerative colitis.
- Depression and anxiety: the prevalence of depressive symptoms was 28% by questionnaire and of clinical depression 12% by ICD codes, and population-based studies gave an OR of 1.57 for depression. In a UK cohort, adjusted hazard ratios for depression, anxiety, and suicidality were 1.39, 1.31, and 1.44, and the hazard ratio for depression was 1.72 in severe and 1.38 in mild psoriasis. Anxiety symptoms had a pooled prevalence of 34% across 101 studies. Among survey respondents with psoriasis or PsA, 52% screened positive for potential major depressive disorder (PHQ-2 score ≥ 3), and depression and anxiety affected 9.1% and 6.3% of the OptumHealth claims cohort.

Source: [Alinaghi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29928910/); [Eder et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26555117/); [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/); [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/); [Gelfand et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17032986/); [Armstrong et al. (2013c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3647278/); [Armstrong et al. (2013a)](https://pubmed.ncbi.nlm.nih.gov/23407990/); [Armstrong et al. (2013b)](https://pubmed.ncbi.nlm.nih.gov/23360868/); [Bellinato et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9184411/); [Fu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583370/); [Dowlatshahi et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24284419/); [Kurd et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928071/); [Jalenques et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9558761/); [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-1.1.1-4"></a>

##### Summary: humanistic burden

- Quality of life: in the UPLIFT online survey in North America, Europe, and Japan, respondents with PsO and/or PsA (n = 3614) had a mean DLQI of 9.3, and the proportion with DLQI > 5 was 56% with limited BSA (≤ 3 palms), 80% with moderate BSA (4–10 palms), and 88% with large BSA (> 10 palms). Among 1529 registry participants on systemic therapy as of 31 May 2016, mean DLQI ranged from 5.2 to 10.2 and mean EQ-VAS from 62.9 (very severe) to 76.4 (mild) across BSA categories. In a U.S. survey of 694 participants, DLQI was higher by 2.97 (moderate vs. mild) and 7.95 (severe vs. mild) and EQ-5D lower by 0.04 and 0.18. In a meta-analysis of 70 utility scores from 59 studies (22 for plaque psoriasis), the mean EQ-5D utility score for plaque psoriasis was 0.755.
- Itch: 92.9% of patients reported pruritus at some time in the course of psoriasis and 81% within the preceding 3 days; in another study, 43% of psoriasis patients named itching as their most bothersome sign or symptom, and 93% of National Psoriasis Foundation survey respondents reported regular pruritus. Mean itching scores ranged from 24.7 to 55.7 across BSA categories in the registry.
- Emotional effects and stigma: among 5,604 National Psoriasis Foundation survey respondents from 2003 to 2011, psoriasis and PsA affected emotional wellbeing in 88%, 87% reported embarrassment, and 83% concealed physical manifestations; 51% of conversations about psoriasis contained negative comments from others. In a U.S. online survey of 793 participants from 2020 to 2021, psoriasis affected emotional well-being in 87% and quality of life in 91%, 36% had been asked if they were contagious, 34% had been stared at in public, and 21% avoided having sex because of their condition or could not stand the thought of someone touching or seeing their skin. In a clinic survey of 106 participants, patient-reported severe psoriasis was associated with “greater anticipation of negative stereotypes, social avoidance, and perceived stigma from others”, and physician-measured BSA and global assessment scores were not significantly associated with any outcome. Psoriasis was associated with sleep disturbance (OR 6.640) across 15 studies.
- Work: in the 2015 Adelphi survey of 936 respondents in the U.S. and five European countries, mean total work productivity loss was 10.1%, 18.9%, and 29.4% in mild, moderate, and severe psoriasis, and mean annual indirect costs per patient were 9591 U.S. dollars in the U.S. In the registry, 7% to 14% were disabled across BSA categories. Among National Psoriasis Foundation survey respondents, 12% were unemployed, of whom 92% cited psoriasis and/or PsA as the sole reasons, and 49% of working respondents missed work days regularly. In the 2020 to 2021 online survey, 29% could not work or study in the week before the survey.

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/); [Strober et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500315/); [Korman et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27061102/); [Yang et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/32716651/); [Jaworecka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304988/); [Lebwohl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576585/); [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/); [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/); [Wan et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7963348/); [Guo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37956475/); [Villacorta et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7497177/)

<a id="topic-1.1.1-5"></a>

##### Summary: economic burden

- National cost: a review of 22 studies estimated the annual U.S. cost of psoriasis at approximately $112 billion in 2013, with direct costs of $51.7 billion to $63.2 billion, indirect costs of $23.9 billion to $35.4 billion, and $36.4 billion attributed to medical comorbidities. A second estimate put the total 2013 burden at $35.2 billion for 7.4 million people: $12.2 billion in incremental medical costs, $11.8 billion from reduced HRQOL, and $11.2 billion from productivity losses.
- Costs by severity: in OptumHealth claims from 2007 to 2012 (2012 U.S. dollars), patients with moderate-to-severe psoriasis (≥ 1 systemic therapy or phototherapy) incurred annual total health care costs of $22,713 vs. $4,993 in matched controls (adjusted difference $18,960), including $14,698 vs. $1,101 for medications; psoriasis-related costs averaged $13,731, of which $12,958 was for systemic therapies. In MarketScan claims from 2009 to 2014 (2014 U.S. dollars), all-cause costs were $12,523 per patient per year overall, $21,481 with moderate-to-severe disease, $23,427 with PsA, and $29,832 on biologics. Another claims study (2019 U.S. dollars) reported annual all-cause costs of $7,470, $11,062, and $29,742 for controls, psoriasis, and PsA. Among 2,130 biologic-treated people, median all-cause total costs were $37.7k (mild), $42.3k (moderate), and $49.3k (severe). At nine U.S. sites, six-month direct costs of moderate-to-severe plaque psoriasis (MSPP) were $11,291 and indirect costs $2101 per patient among 200 adults seeking MSPP treatment.
- Costs by treatment: annual medication costs were $21,977 for biologics and $3413 for oral systemics in U.S. dermatology records. Among patients initiating biologics, the average annual treatment cost, estimated from net prices accounting for average manufacturer rebates, rose from $21,236 in 2007 to $47,125 in 2021, with a 2021 range of $12,413 (infliximab) to $70,043 (risankizumab); initiating the lowest-cost medication in each class would have lowered the 2021 average by 44% ($26,363). Compared with nonswitchers, biologic switchers had higher adjusted total costs (mean difference $10,120) and discontinuers lower costs (−$18,611).
- Comorbidity and work costs: compared with controls, psoriasis patients incurred higher total health care costs by $1,590, $5,870, and $18,427 with 0, 1-2, and ≥3 comorbidities, and higher work-loss costs by $335, $655, and $1,695. Per patient per month cost differences in moderate to severe psoriasis included $372 for mental health, $305 for hypertension, and $360 for liver disease. Among 452 employed participants of the CLEAR trial, mean annual indirect costs per worker were $10,318 with PASI < 50 and $2,233 with PASI ≥ 90.
- Out-of-pocket spending: survey respondents reported mean out-of-pocket costs of $240 per month for healthcare and $147 per month for nonprescription medicines, creams, and lotions.

Source: [Brezinski et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25565304/); [Vanderpuye-Orgle et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25882886/); [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/); [Al Sawah et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28635342/); [Merola et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33934270/); [Murage et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29718756/); [Schaefer et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26253364/); [Armstrong et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6025830/); [Rome et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12004245/); [Feldman et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398133/); [Pilon et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30523738/); [Wu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9823180/); [Feldman et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398100/); [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)

<a id="topic-1.1.1-6"></a>

##### Summary: burden on families

- Among 63 relatives and partners, seventy percent spent extra time on housework because of the patient's treatment, 57% described psychological pressures, 55% social disruption, and 37% deterioration of close relationships; 8% described no effect on their quality of life. Their quality of life correlated more closely with the patient's DLQI (r = 0.77) than with PASI (r = 0.34).
- In a prospective study of 556 people with psoriasis and their partners at 11 centers in Austria, Canada, Germany, Italy, Spain, and Turkey, partner burden increased with severity in each domain, with the highest scores for emotional strain and cleaning.
- Of 153 close relatives and partners of 250 registry participants with mostly treatment-controlled disease, 78.7% of male and 77.3% of female relatives and partners had a small or larger disease burden.
- Psoriasis impaired the quality of life of 87.8% of cohabitants, whose FDLQI scores correlated with patients' DLQI scores (rs = 0.554).
- In a clinic sample of 83 participants, family income correlated negatively with severity (Spearman's rho = -0.356); mean PASI was 20.5 with family income below the social minimum and 11.7 with higher income.
- Across 21 studies of 1161 caregivers of children with psoriasis, 96.1% of caregivers experienced some degree of HrQOL impairment, which correlated with child disease severity (r = 0.463).

Source: [Eghlileb et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17459044/); [Mrowietz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436565/); [Grossschaedl et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11150751/); [Martínez-García et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24836080/); [Hawro et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24852054/); [Perlmutter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13423114/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Envudeucitinib Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: ONWARD1 and ONWARD2 phase 3 trials

ONWARD1 and ONWARD2 are two parallel global, multicenter, randomized, double-blind, placebo- and active-comparator-controlled 24-week trials in adults with moderate-to-severe plaque psoriasis. Participants were randomized 2:1:1 to envudeucitinib 40 mg twice daily, placebo, or apremilast, and placebo participants rolled over to envudeucitinib at week 16. The co-primary endpoints were PASI 75 and sPGA 0/1 against placebo at week 16. Enrollment is reported as 912 (ONWARD1) and 862 (ONWARD2) participants in the ClinicalTrials.gov records, as arm sizes of 459, 230, and 223 (ONWARD1) and 433, 211, and 215 (ONWARD2) in the congress presentation, and as “N=1771” for both trials in a company press release. The ONWARD1 and ONWARD2 results come from company press releases, a company webcast presentation, and congress presentations and posters by Blauvelt et al. and Hawkes et al.; both ClinicalTrials.gov records read “No Results Posted”.

The topline press release states that envudeucitinib was superior to placebo on both co-primary endpoints in each trial (p < 0.0001). At week 16, PASI 75 was achieved by 76.5% of envudeucitinib, 18.7% of placebo, and 44.4% of apremilast participants in ONWARD1, and by 70.4%, 13.7%, and 38.6% in ONWARD2. sPGA 0/1 is quoted only as an average across both trials: 59% in the topline press release and approximately 60% at week 16 in the congress presentation.

Against apremilast, PASI 90 at week 16 was 59.9% vs 21.5% in ONWARD1 and 53.1% vs 20.9% in ONWARD2, and PASI 100 was 29.4% vs 4.0% and 27.7% vs 7.9% (placebo: PASI 90 4.8% and 4.3%, PASI 100 0.9% in each trial). At week 24, PASI 90 was 68.0% vs 25.6% in ONWARD1 and 62.1% vs 25.6% in ONWARD2, and PASI 100 was 41.0% vs 8.5% and 39.5% vs 13.0%. The topline press release states that envudeucitinib was superior to apremilast in each trial (p<0.0001) on all PASI endpoints at week 24.

Itch and quality-of-life results are reported for both trials together. The congress presentation reports a mean decrease of more than 4 points from baseline in worst pruritus NRS by week 12, and a press release reports an average improvement of more than 4 points by week 16. Approximately one-third of envudeucitinib participants had an improvement of at least 4 points at week 2. At week 16, complete itch resolution (NRS 0) is reported as “over one-third” in the itch poster and about 40% in a press release, and minimal itch (NRS 0/1) as more than half and approximately 60%, respectively. A press release reports that approximately 50% achieved DLQI 0/1 by week 12; the DLQI 0/1 endpoint was assessed in participants with baseline DLQI of at least 2.

In the pooled safety population through week 16, at least one TEAE occurred in 524 of 890 envudeucitinib participants (58.9%), 166 of 441 placebo participants (37.6%), and 223 of 438 apremilast participants (50.9%); SAEs occurred in 19 (2.1%), 5 (1.1%), and 5 (1.1%), and TEAEs leading to discontinuation in 30 (3.4%), 7 (1.6%), and 9 (2.1%). Through week 16, rates of headache were 10.3%, 2.5%, and 9.1%, nasopharyngitis 7.2%, 4.8%, and 3.7%, acne 6.0%, 0.7%, and 0.7%, diarrhea 1.6%, 2.5%, and 8.2%, and nausea 2.2%, 0.9%, and 5.3%. Through week 24, the overall envudeucitinib group (n = 1280) had TEAEs in 693 participants (54.1%), SAEs in 25 (2.0%), and TEAEs leading to discontinuation in 35 (2.7%), compared with 248 (56.6%), 6 (1.4%), and 12 (2.7%) in the apremilast group (n = 438). The congress presentation reports serious infections in 0.7% and malignancies in 0.2% of envudeucitinib participants at week 24, no deaths, no MACE or cytopenia signals, and no tuberculosis reactivation; thirty-nine participants with latent or treated tuberculosis were enrolled.

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738); [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib); [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm); [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm); [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf); [Blauvelt et al. (2026d)](https://www.alumis.com/file.cfm/613/docs/esk2507192m_eadv-2026-onward-topline-encore-poster_14sep2026-2.pdf); [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="topic-1.1.2-2"></a>

##### Summary: ONWARD3 long-term extension

ONWARD3 is an ongoing phase 3 long-term extension that participants completing week 24 of ONWARD1 or ONWARD2 were eligible to enter. All entrants received open-label envudeucitinib for 24 weeks regardless of parent-study treatment; the first 200 participants achieving PASI 75 at week 24 of ONWARD3 could enter a 24-week randomized withdrawal period, and the trial is designed to provide up to 96 weeks of data. Enrollment is given as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 entrants from the envudeucitinib, placebo, and apremilast arms of the parent trials (congress poster).

In a non-responder imputation analysis of the 773 participants from the envudeucitinib arms, with up to 48 weeks of continuous treatment, 75% achieved PASI 90 and 54% achieved PASI 100 (press release); the poster reports PASI 75 in 85.2%, sPGA 0/1 in 75.2%, and sPGA 0 in 54.5% of those continuously treated at week 48. A separate integrated non-responder imputation analysis of the 890 participants originally randomized to envudeucitinib, including those who did not enter ONWARD3, reports PASI 90 in 66% and PASI 100 in 47% after 48 weeks. Among participants with a response at the end of the parent trials, the response was maintained after 24 weeks in ONWARD3 by 89.8% for PASI 75 (n = 678), 89.4% for PASI 90 (n = 575), 80.1% for PASI 100 (n = 357), 86.2% for an improvement of at least 4 points in worst pruritus NRS (n = 509), and 86.3% for DLQI 0/1 (n = 497).

Through week 48, at least one TEAE occurred in 521 (67.4%), 253 (68.9%), and 268 (72.6%) participants from the envudeucitinib, placebo, and apremilast parent arms, SAEs in 25 (3.2%), 16 (4.4%), and 9 (2.4%), and TEAEs leading to discontinuation in 23 (3.0%), 11 (3.0%), and 25 (6.8%). The poster reports no deaths, MACE events, lymphomas, or tuberculosis reactivation, and three positive tuberculosis tests without clinical signs or symptoms. Results of the randomized withdrawal period have not been reported.

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541); [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm); [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-1.1.2-3"></a>

##### Summary: STRIDE phase 2 trial and its open-label extension

STRIDE was a phase 2, randomized, double-blinded, placebo-controlled, 16-week study (12 weeks of treatment and 4 weeks of safety follow-up) in which 228 participants were randomized and 227 dosed with placebo or envudeucitinib 10 mg QD, 20 mg QD, 40 mg QD, 20 mg BID, or 40 mg BID. At week 12 (modified intent-to-treat set, nonresponder imputation), the primary endpoint of PASI 75 was achieved by 0 of 38 placebo participants (0%) and by 19%, 33%, 56%, 56%, and 64% in the 10 mg QD, 20 mg QD, 20 mg BID, 40 mg QD, and 40 mg BID arms (P < .0001 for 40 mg BID). With 40 mg BID, 39% achieved PASI 90, 15% PASI 100, 59% sPGA 0/1 (placebo 8%), and 64% DLQI 0/1 (placebo 18%), and the average pruritus NRS improved by 5 points (placebo 1 point). In the safety analysis set of the 16-week study, TEAEs occurred in 25 of 39 participants (64.1%) receiving 40 mg BID, 95 of 189 (50.3%) receiving any envudeucitinib dose, and 15 of 38 (39.5%) receiving placebo; SAEs occurred in 5 envudeucitinib participants (2.6%) and in none receiving 40 mg BID or placebo, and 5 participants (2.6%) discontinued envudeucitinib due to an AE. There were no deaths and no cases of tuberculosis, herpes zoster, opportunistic infections, or oral ulcers. An exposure-response analysis supported selection of 40 mg BID for the phase 3 trials.

In the open-label extension, 165 participants who completed STRIDE were enrolled at North American sites and assigned to 40 mg QD or 40 mg BID; a protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64. At week 52 with 40 mg BID, the article text reports PASI 75 in 78%, PASI 90 in 61%, PASI 100 in 39%, sPGA 0 in 39%, and DLQI 0/1 in 61% of participants; the efficacy table gives PASI 100 as 31 of 80 (38.8%) in the original 40 mg BID group and 47 of 144 (32.6%) in the overall 40 mg BID group. Through week 52 (safety analysis population, N = 164), at least one TEAE occurred in 108 participants (65.9%), at least one SAE in 6 (3.7%), and a TEAE leading to study drug discontinuation in 6 (3.7%). Four SAEs were considered related to study drug (peritonsillar abscess, non-small cell lung cancer, renal cell carcinoma, and arthritis); 2 cases of herpes zoster occurred, and there were no deaths and no cases of tuberculosis.

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [Ucpinar et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv2024_pstr_poppk-er_final.pdf); [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-1.1.2-4"></a>

##### Summary: phase 1 studies

In the first-in-human study (ACTRN12621000011886), 91 participants were enrolled, 53 in the single ascending dose part and 38 in the multiple ascending dose part, and received a liquid formulation; single doses of 5, 10, 17.5, 25, 50, and 100 mg were given (planned range 5 to 150 mg). The ANZCTR record gives a final sample size of 87. After single doses, median Tmax was 0.8 to 1.1 h and mean terminal half-life 7.5 to 9.3 h. With the liquid formulation at 25 mg, a high-calorie meal reduced Cmax by approximately 50% and delayed median Tmax from 0.75 h to 4 h, with similar AUC0–inf. In the single ascending dose part, TEAEs occurred in 32 participants receiving envudeucitinib (78.0%) and 5 receiving placebo (41.6%), there were no serious TEAEs, and headache was the most common TEAE.

In the 14-day multiple-dose study of the immediate release tablet (ESK-001-003), 49 participants were enrolled (36 envudeucitinib, 13 placebo). The mean half-life after the last dose on Day 14 ranged from 7.6 to 12.4 h, steady state was achieved by Day 3, dosing every 12 hours produced approximately 2-fold accumulation, and trough concentrations at 40 mg Q12 remained above the in vitro human whole blood 90% pSTAT inhibitory concentration. TEAEs occurred in 27 envudeucitinib (75.0%) and 11 placebo (84.6%) participants. Across the first-in-human and multiple-dose studies, no deaths, serious TEAEs, or severe TEAEs were reported, and a concentration-QTc analysis excluded a placebo-corrected QTcF effect exceeding 10 ms at plasma concentrations up to approximately 1000 ng/mL.

In the pharmacokinetic study in Japanese, Chinese, and Caucasian healthy participants (24 participants in cohorts of 8), the steady-state half-life on Day 7 of 40 mg BID was 7.6, 8.4, and 9.1 h; the poster reports similar pharmacokinetic and safety profiles across ethnicities, no serious TEAEs or deaths, and 1 discontinuation (Caucasian cohort, 40 mg BID) for a moderate headache. The QT study ESK-001-019 (52 participants), the hepatic impairment study ESK-001-022 (32), the renal impairment study ESK-001-023 (16), and the tablet and liquid relative bioavailability study ESK-001-002 (14) are completed, and their ClinicalTrials.gov records read “No Results Posted”.

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/); [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885); [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634); [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf); [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579); [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634); [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774); [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Envudeucitinib

<a id="topic-1.1.3-1"></a>

##### Summary: price and economic analyses of envudeucitinib

Envudeucitinib is “an investigational drug, not reviewed or approved by any regulatory agency”, and Alumis plans to submit its New Drug Application to the FDA in the fourth quarter of 2026. The report records no price for envudeucitinib, no budget impact model, and no published economic analysis that includes it. In its annual report, Alumis states that its projections of the number of people with the diseases it aims to address, and of those who could benefit from its product candidates, “are based on our beliefs and estimates” and that pricing of competitive products may limit the amount it will be able to charge for its product candidates, if approved.

Source: [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/); [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm); [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-1.1.3-2"></a>

##### Summary: comparator prices by source and date

Package prices are given as each file lists them, in U.S. dollars.

- Deucravacitinib (Sotyktu): WAC price 7135.55 in the Texas DSHS 2026 annual WAC report; for SOTYKTU 6MG TAB, package of 30, an FSS price of 6088.27 and a Big Four price of 4815.81 from 01/01/2026 in the Department of Veterans Affairs file. Bristol Myers Squibb states that beginning January 2026, eligible cash-pay U.S. patients can buy Sotyktu through BMS Patient Connect at more than 80% less than the current list price.
- Icotrokinra (ICOTYDE): 200mg tablet, package size 30, WAC at introduction 8285.0000 on 2026-03-18 (California HCAI new prescription drugs file).
- Apremilast (Otezla): 5589.89 for the 30mg 60 pack and for the 75 mg extended-release 30 pack, effective 01/07/2026 (California HCAI WAC increase file). The Medicare negotiated price for Otezla and Otezla XR is $1,650 for a 30-day supply in CY 2027, against a CY 2024 list price of $4,722 for a 30-day supply, a 65% discount.
- Injectable biologics: SKYRIZI 150 mg pen 23838.42 (effective 01/02/2026), COSENTYX 300 mg pen 8492.03 (effective 01/07/2026), and SILIQ 210 mg box of 2 syringes 6928.92 (effective 05/11/2026) in the California HCAI WAC increase file; TREMFYA 14566.44, STELARA 29151.48, Otulfi 45 mg 1809.79, and SELARSDI 45 mg 2088.21 in the Texas DSHS 2026 annual WAC report.
- Cosentyx and Cimzia are among the drugs selected for the third cycle of Medicare negotiation, with any negotiated prices effective beginning in 2028.

Source: [Texas DSHS 2026 annual WAC report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx); [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx); [Bristol Myers Squibb press release, BMS Patient Connect platform (2025)](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx); [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI prescription drug WAC increases, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv); [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf); [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)

<a id="topic-1.1.3-3"></a>

##### Summary: eligible population and U.S. economic burden

- Prevalence: approximately 3.0% of U.S. adults aged 18 years and older reported a history of psoriasis, approximately 7.9 million adults in 2023 (National Health Interview Survey, Smith et al.); psoriasis prevalence among U.S. adults 20 years or older was 3.0%, approximately 7.55 million adults based on 2020 census data (NHANES, Armstrong et al.). The manufacturer of icotrokinra states in its California filing that over 8 million people in the US are living with psoriasis and that exact information for the indicated population is not available in the public domain.
- Moderate-to-severe fraction: 21.5% of participants reported moderate to severe psoriasis (3 or more palms of body surface area) (NHANES, Armstrong et al.); 18.2% reported moderate or severe disease (Helmick et al.); 16.63% of those with a physician diagnosis had disease covering 3% or greater body surface area, with an estimated 1.4 million people age 20 to 59 with moderate to severe disease (Kurd and Gelfand).
- Insured and untreated: an estimated 1.7 million insured U.S. patients had moderate to severe psoriasis, of whom 1 million (59%) were not treated for their condition in the preceding year; in the 5-year analysis window, 546,814 of 1,700,266 (32.2%) were diagnosed but not treated, and 40.9% were receiving therapy in the 12 months up to September 2012 (health-plan claims, Armstrong et al.).
- Economic burden: the annual U.S. cost of psoriasis amounted to approximately $112 billion in 2013 in a systematic review of 22 studies (Brezinski et al.), and the total burden was estimated at $35.2 billion in another 2013 estimate (Vanderpuye-Orgle et al.). Adults aged 18 to 64 with moderate-to-severe psoriasis had annual total health care costs of $22,713 per patient against $4,993 for matched controls, in 2012 U.S. dollars (Feldman et al.). All-cause health care costs per patient per year were $21,481 for moderate-to-severe disease and $29,832 for patients on biologics, in 2014 US dollars (Al Sawah et al.). Among patients initiating biologics, the average annual treatment cost, using commercial estimates of net prices, rose from $21,236 in 2007 to $47,125 in 2021 (Rome et al.).

Source: [Smith et al. (2025)](https://www.jaad.org/article/S0190-9622%2824%2903365-6/fulltext); [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/); [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [Helmick et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4653077/); [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/); [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/); [Brezinski et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25565304/); [Vanderpuye-Orgle et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25882886/); [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/); [Al Sawah et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28635342/); [Rome et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12004245/)

<a id="topic-1.1.3-4"></a>

##### Summary: ICER assessments and published budget impact analyses of comparators

- ICER 2016 report: the candidate population was adults with moderate-to-severe plaque psoriasis taking a biologic agent for the first time, approximately 36,750 incident cases per year. The budget impact threshold for 2015-16 was $904 million per year for new drugs; the total potential budgetary impact over five years was approximately $1.2 billion for brodalumab ($239.8 million per year) and approximately $1.3 billion for ixekizumab ($266 million per year).
- ICER 2018 report: the same candidate population gave an average of 29,342 incident cases of moderate-severe plaque psoriasis per year, approximately 146,710 over five years. At all prices except the price to reach $50,000 per QALY, the annual potential budgetary impact for the entire eligible population exceeded the annual threshold of $915 million; the additional per-patient cost averaged approximately $58,900 at WAC and approximately $37,200 with the assumed discount. At a $50K/QALY threshold no targeted drug offered good value, and discounts of 38% to 71% were required to reach $100,000 per QALY.
- Carrico et al.: in a health plan of 1 million members with an estimated 1048 patients receiving biologics or apremilast for psoriasis, adding tildrakizumab reduced total health plan cost by a cumulative $964,763 over 5 years, with per member per month reductions of $0.03 or less.
- Feldman et al.: in a hypothetical commercial health plan of two million members with 7,038 patients estimated to be eligible, brodalumab use of 3% to 30% reduced the total annual pharmacy cost by $3,698,129 to $36,981,290.
- Park et al.: the cost per response of deucravacitinib was lower than that of apremilast at 16 weeks (difference -$3796) and 24 weeks (difference -$12,784).

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf); [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf); [Carrico et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7688845/); [Feldman et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29357713/); [Park et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38914425/)

<a id="topic-1.1.3-5"></a>

##### Summary: market statements by Alumis

In its corporate presentation, Alumis describes psoriasis as a “Large marketplace with modest treatment penetration” and states that the uptake of Icotyde is largely additive and that historical market share trends show a multi-winner market. The presentation reports that 84% of patients and 73% of dermatologists believe there is a need for better psoriasis therapies.

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

- Status: envudeucitinib is “an investigational drug, not reviewed or approved by any regulatory agency”, and Alumis plans to submit its New Drug Application to the FDA for moderate-to-severe plaque psoriasis in the fourth quarter of 2026. The Alumis Form 10-Q for the third quarter of 2026 states that cash, cash equivalents, and marketable securities of $431.3 million as of September 30, 2026 will not be sufficient to meet its operating and capital requirements for at least 12 months and that there is “substantial doubt about the Company’s ability to continue as a going concern”. The third-quarter results press release states that the same resources as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.
- ONWARD1 and ONWARD2: in these phase 3 trials, participants were randomized to envudeucitinib 40 mg twice daily, placebo, or apremilast. At week 16, PASI 75 was achieved by 76.5% of envudeucitinib, 18.7% of placebo, and 44.4% of apremilast participants in ONWARD1 and by 70.4%, 13.7%, and 38.6% in ONWARD2. At week 24, PASI 100 was achieved by 41.0% of envudeucitinib and 8.5% of apremilast participants in ONWARD1 and by 39.5% and 13.0% in ONWARD2. In the pooled safety population through week 16, TEAEs occurred in 58.9%, 37.6%, and 50.9% of envudeucitinib, placebo, and apremilast participants, SAEs in 2.1%, 1.1%, and 1.1%, TEAEs leading to discontinuation in 3.4%, 1.6%, and 2.1%, and acne in 6.0%, 0.7%, and 0.7%.
- ONWARD3: in the long-term extension, a non-responder imputation analysis of 773 participants from the envudeucitinib arms who received up to 48 weeks of continuous treatment reported PASI 90 in 75% and PASI 100 in 54%. A separate integrated non-responder imputation analysis of the 890 participants originally randomized to envudeucitinib, including those who did not enter ONWARD3, reported 66% and 47% after 48 weeks.
- STRIDE: in the phase 2 trial, 228 participants were randomized to placebo or one of five envudeucitinib doses, and PASI 75 at week 12 was achieved by 64% with 40 mg BID and 0% with placebo (P < .0001). In the open-label extension, after 52 weeks of 40 mg twice daily, the article text reports PASI 75 in 78%, PASI 90 in 61%, and PASI 100 in 39%; its efficacy table gives PASI 100 as 38.8% in the original 40 mg BID group and 32.6% in the overall 40 mg BID group. In the extension safety analysis set (164 participants), 65.9% had at least one TEAE and 3.7% discontinued study drug due to AEs.
- Comparators and comparison evidence: the oral comparators in the report are deucravacitinib, apremilast, and icotrokinra, each with a U.S. prescribing information, and zasocitinib, whose NDA the FDA accepted under Priority Review with a PDUFA target action date in the first quarter of calendar year 2027. The active comparator of ONWARD1 and ONWARD2 is apremilast, and the report holds no trial of envudeucitinib against deucravacitinib, icotrokinra, zasocitinib, or a biologic. A review whose medical writing Alumis funded states that direct and formal indirect comparisons of oral agents “are not presently available”. Icotrokinra and zasocitinib have each been compared with deucravacitinib: week 16 PASI 90 was 55% with icotrokinra and 30% with deucravacitinib in Trial PSO-1 of the icotrokinra label, and week 16 PASI 100 was 36.5% with zasocitinib and 13.9% with deucravacitinib in LATITUDE Atlas. The Alumis corporate presentation sets the ONWARD week 24 PASI 100 rates (41.0% and 39.5%) beside those of icotrokinra (41.5% and 33.2%) and zasocitinib (42.3% and 32.1%) in a “retrospective post hoc cross-trial comparison” whose results it states “may not be directly comparable”.
- Evidence gaps: the ONWARD1, ONWARD2, and ONWARD3 results come from company press releases, company presentations, and congress posters; the report holds no peer-reviewed ONWARD publication, and the ClinicalTrials.gov records of ONWARD1 and ONWARD2 read “No Results Posted”. The report holds no participant disposition data for ONWARD1 or ONWARD2 and no subgroup results for envudeucitinib. Four completed studies (a QT study, a hepatic impairment study, a renal impairment study, and a tablet and liquid relative bioavailability study) have no posted results. A narrative review states that long-term safety data for zasocitinib and envudeucitinib “are not yet available”, and Alumis plans to report two-year phase 2 safety data in the fourth quarter of 2026.
- Price and economic analyses: the report records no price, budget impact model, or published economic analysis for envudeucitinib. Package prices of the oral comparators include a Sotyktu WAC price of 7135.55 in the Texas DSHS 2026 annual WAC report, an ICOTYDE 200mg 30-tablet WAC at introduction of 8285.0000 on 2026-03-18 in the California HCAI new prescription drugs file, and an Otezla 30mg 60 pack price of 5589.89 effective 01/07/2026 in the California HCAI WAC increase file.

Source: [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/); [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm); [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm); [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf); [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm); [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm); [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext); [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf); [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf); [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf); [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/); [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/); [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/); [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2); [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4); [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738); [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579); [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634); [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774); [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858); [Texas DSHS 2026 annual WAC report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx); [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI prescription drug WAC increases, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
